NASDAQ$ADMA
ADMA Biologics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
ADMA Biologics achieved record revenue growth and narrowed net losses in Q2 2021.
ADMA Biologics reported a record $17.8 million in total revenues for Q2 2021, a 129% increase over the same period in 2020. The company also narrowed its net loss compared to the previous year, driven by increased revenues and improved gross margins. ADMA anticipates exiting 2021 approaching an annualized revenue run rate of approximately $100 million or more.
- Total revenues increased by 129% to $17.8 million compared to Q2 2020.
- Net loss narrowed to $18.9 million, or $(0.15) per share, compared to a net loss of $20.2 million, or $(0.23) per share, in Q2 2020.
- Company anticipates FDA approval of VanRx aseptic fill-finish machine in the second half of 2021.
- ADMA is on track to operate 10 or more plasma collection centers by 2024.
Headline financials
Revenue & EPS history
ADMA Biologics · Revenue · Quarterly
$17.8M
Forward guidance
ADMA anticipates exiting 2021 approaching an annualized revenue run rate of approximately $100 million or more and reiterates all previously communicated strategic and financial objectives.
Tailwinds
- Anticipated benefits from the VanRx aseptic fill-finish machine, including cost efficiencies and contract manufacturing opportunities
- Expected benefits from the recent implementation of Haemonetics’ Persona® technology combined with our plasma collection network
- Goal of building and opening new plasma collection centers by 2024
- Meaningful gross margin improvement
- Operating efficiencies
Headwinds
- Risks and uncertainties described in our filings
- Impact of COVID-19 on the Company’s financial results and business operations
- Company’s plasma collections and production
- Our ability to maintain plasma supply
- The outcome and timing of our BLA application for our new plasma centers and for FDA approval of our VanRx aseptic fill-finish machine
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+2.5%
Avg return
Earnings day
+3.7%
Avg return
5 days after
+6.4%
Avg return
30 days after
50%
20 / 40 earnings
Positive
+39.4%
Q2 2024
Best reaction
-17.4%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.7% | -23.1% | -22.2% | |
| Q4 2025 | -3.6% | +4.5% | -41.0% | |
| Q3 2025 | -8.4% | +4.3% | +29.1% | |
| Q1 2025 | -10.2% | -15.8% | -12.7% | |
| Q4 2024 | +7.5% | +7.5% | +22.9% | |
| Q3 2024 | +15.0% | +10.7% | +0.8% | |
| Q2 2024 | +39.4% | +50.8% | +42.0% | |
| Q1 2024 | +28.4% | +33.5% | +52.6% | |
| Q4 2023 | -2.9% | +3.6% | +19.6% | |
| Q3 2023 | +3.8% | +1.4% | +0.5% | |
| Q2 2023 | +4.1% | +11.4% | -7.2% | |
| Q1 2023 | +14.1% | +20.7% | +10.1% | |
| Q4 2022 | +10.3% | +6.6% | +18.9% | |
| Q3 2022 | +20.7% | +26.8% | +36.0% | |
| Q2 2022 | +9.9% | +18.7% | +40.4% | |
| Q1 2022 | +4.3% | +16.1% | +20.5% | |
| Q4 2021 | +11.6% | +25.3% | +36.3% | |
| Q3 2021 | +12.0% | +9.2% | -6.3% | |
| Q2 2021 | -1.9% | -6.5% | -22.7% | |
| Q1 2021 | -6.4% | +0.0% | +5.2% | |
| Q4 2020 | -8.6% | -13.6% | -4.0% | |
| Q3 2020 | -10.7% | -15.0% | -6.5% | |
| Q2 2020 | -15.1% | -9.8% | -34.1% | |
| Q1 2020 | -17.4% | -15.8% | -6.2% | |
| Q4 2019 | -6.5% | -13.4% | +18.2% | |
| Q3 2019 | -12.1% | -14.6% | -16.0% | |
| Q2 2019 | +3.9% | +15.2% | +40.3% | |
| Q1 2019 | +7.7% | -1.0% | -21.3% | |
| Q4 2018 | +0.0% | +7.9% | +25.4% | |
| Q3 2018 | -8.7% | -11.3% | -17.7% | |
| Q2 2018 | -4.1% | -6.5% | +0.3% | |
| Q1 2018 | +5.8% | +9.0% | -4.0% | |
| Q4 2017 | -0.3% | +10.5% | +26.8% | |
| Q3 2017 | -6.8% | -2.0% | +35.1% | |
| Q2 2017 | +1.7% | +4.8% | +17.9% | |
| Q1 2017 | +0.7% | -8.3% | -18.4% | |
| Q4 2016 | -0.6% | -5.0% | +0.8% | |
| Q3 2016 | +17.9% | +17.0% | -3.3% | |
| Q2 2016 | +6.4% | -9.2% | -7.2% | |
| Q4 2014 | +0.0% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro